Therapeutic effects of simvastatin combined with kallistatin treatment for pediatric burn patients with sepsis

Dai,Yefeng; Zhao,Xufei

doi:10.3892/etm.2018.5791

Therapeutic effects of simvastatin combined with kallistatin treatment for pediatric burn patients with sepsis

Authors:
- Yefeng Dai
- Xufei Zhao
View Affiliations

Affiliations: Department of Burns and Plastic Surgery, Children's Hospital Affiliated to The Medical College of Zhejiang University, Hangzhou, Zhejiang 310000, P.R. China
Published online on: January 24, 2018 https://doi.org/10.3892/etm.2018.5791
Pages: 3080-3087

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to examine the combined efficacy of simvastatin and kallistatin treatment for pediatric burn sepsis. A total of 72 pediatric patients with burn sepsis were recruited and randomly divided into 3 groups, receiving simvastatin (40 mg/day), kallistatin (20 mg/day) or combined treatment. ELISA, reverse transcription‑quantitative polymerase chain reaction, western blotting and flow cytometry were used to analyze the therapeutic effects of simvastatin and kallistatin. The results revealed that combined treatment in pediatric burn sepsis patients decreased the inflammatory cytokine tumor necrosis factor α and interleukin (IL)‑1β serum levels, whereas it increased IL‑10 and human leukocyte antigen‑D related levels. In addition, administration of combined simvastatin and kallistatin decreased the blood urea nitrogen and serum creatinine levels in the patients. It was also demonstrated that Toll‑like receptor 4 expression on the surface of monocytes was markedly decreased, while suppressor of cytokine signaling‑3 expression was increased in the combined treatment group as compared with the kallistatin or simvastatin treatment alone. Combined treatment also promoted human endothelial cell (HEC) growth compared with the single treatment groups and inhibited the high mobility group box‑1 (HMGB1) levels, HMGB1‑induced nuclear factor‑κB activation and inflammatory gene expression levels in these cells. The study further demonstrated that combined treatment significantly decreased HEC apoptosis through the upregulation of B‑cell lymphoma 2 (Bcl‑2) and P53 expression levels, as well as downregulation of Bcl‑2‑associated X protein and caspase‑3 levels. In conclusion, these observations indicated that combined treatment with simvastatin and kallistatin inhibited HEC apoptosis, which may be a potential therapeutic strategy for the treatment of pediatric burn sepsis patients.

View Figures

View References

1	Housinger TA, Brinkerhoff C and Warden GD: The relationship between platelet count, sepsis, and survival in pediatric burn patients. Arch Surg. 128:65–67. 1993. View Article : Google Scholar : PubMed/NCBI
2	Yu T, Stockmann C, Healy DP, Olson J, Wead S, Neely AN, Kagan RJ, Spigarelli MG and Sherwin CM: Determination of optimal amikacin dosing regimens for pediatric patients with burn wound sepsis. J Burn Care Res. 36:e244–e252. 2015. View Article : Google Scholar : PubMed/NCBI
3	Sheridan RL: Sepsis in pediatric burn patients. Pediatr Crit Care Med. 6 3 Suppl:S112–S119. 2005. View Article : Google Scholar : PubMed/NCBI
4	Peng YZ: Clinical characteristics and diagnosis of sepsis in pediatric burn patients. Zhonghua Shao Shang Za Zhi. 29:1–3. 2013.(In Chinese). PubMed/NCBI
5	Scott HF, Paul R and Balamuth F: The spectrum of pediatric sepsis: ‘Septicemia’ misses severe cases. Ann Emerg Med. 66:685–686. 2015. View Article : Google Scholar : PubMed/NCBI
6	Ruth A, McCracken CE, Fortenberry JD and Hebbar KB: Extracorporeal therapies in pediatric severe sepsis: Findings from the pediatric health-care information system. Crit Care. 19:3972015. View Article : Google Scholar : PubMed/NCBI
7	Odetola FO, Gebremariam A and Freed GL: Patient and hospital correlates of clinical outcomes and resource utilization in severe pediatric sepsis. Pediatrics. 119:487–494. 2007. View Article : Google Scholar : PubMed/NCBI
8	Alexandre-Treilles M, Chenaud M, Kacet N, Ego A and Truffert P; OMBREL de Soins Périnatals de Lille Métropole, : Pediatric management of early-onset neonatal sepsis: Guidelines adherence in Lille's perinatal care network. Arch Pediatr. 13:341–345. 2006.(In French). View Article : Google Scholar : PubMed/NCBI
9	Moloney-Harmon PA: Pediatric sepsis: The infection unto death. Crit Care Nurs Clin North Am. 17:417–429, xi. 2005. View Article : Google Scholar : PubMed/NCBI
10	Ramadan WH and Kabbara WK: Sitagliptin/Simvastatin: A first combination tablet to treat type 2 diabetes and hypercholesterolemia-a review of its characteristics. Vasc Health Risk Manag. 11:125–132. 2015. View Article : Google Scholar : PubMed/NCBI
11	Taveira-DaSilva AM, Jones AM, Julien-Williams PA, Stylianou M and Moss J: Retrospective review of combined sirolimus and simvastatin therapy in lymphangioleiomyomatosis. Chest. 147:180–187. 2015. View Article : Google Scholar : PubMed/NCBI
12	Yasuda H, Yuen PS, Hu X, Zhou H and Star RA: Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int. 69:1535–1542. 2006. View Article : Google Scholar : PubMed/NCBI
13	Souza Neto JL, Araújo Filho I, Rego AC, Dominici VA, Azevedo IM, Egito ES, Brandão-Neto J and Medeiros AC: Effects of simvastatin in abdominal sepsis in rats. Acta Cir Bras. 21 Suppl 4:S8–S12. 2006. View Article : Google Scholar
14	Beffa DC, Fischman AJ, Fagan SP, Hamrahi VF, Paul KW, Kaneki M, Yu YM, Tompkins RG and Carter EA: Simvastatin treatment improves survival in a murine model of burn sepsis: Role of interleukin 6. Burns. 37:222–226. 2011. View Article : Google Scholar : PubMed/NCBI
15	Fu H, Wang QS, Luo Q, Tan S, Su H, Tang SL, Zhao ZL and Huang LP: Simvastatin inhibits apoptosis of endothelial cells induced by sepsis through upregulating the expression of Bcl-2 and downregulating Bax. World J Emerg Med. 5:291–297. 2014. View Article : Google Scholar : PubMed/NCBI
16	Wang CR, Chen SY, Wu CL, Liu MF, Jin YT, Chao L and Chao J: Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum. 52:1319–1324. 2005. View Article : Google Scholar : PubMed/NCBI
17	Shen B, Hagiwara M, Yao YY, Chao L and Chao J: Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension. 51:1358–1365. 2008. View Article : Google Scholar : PubMed/NCBI
18	Yin H, Gao L, Shen B, Chao L and Chao J: Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation. Hypertension. 56:260–267. 2010. View Article : Google Scholar : PubMed/NCBI
19	Li P, Guo Y, Bledsoe G, Yang ZR, Fan H, Chao L and Chao J: Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsis. Crit Care. 19:2002015. View Article : Google Scholar : PubMed/NCBI
20	Chai JK: Diagnosis and comprehensive management of sepsis after burn. Zhonghua Shao Shang Za Zhi. 29:105–108. 2013.PubMed/NCBI
21	Maguire PJ, Power KA, Downey AF, O'Higgins AC, Sheehan SR and Turner MJ: Evaluation of the systemic inflammatory response syndrome criteria for the diagnosis of sepsis due to maternal bacteremia. Int J Gynaecol Obstet. 133:116–119. 2016. View Article : Google Scholar : PubMed/NCBI
22	Hautamäki A, Luoma A and Immonen I: Anterior chamber flare during bevacizumab treatment in eyes with exudative age-related macular degeneration. Retina. 36:2183–2190. 2016. View Article : Google Scholar : PubMed/NCBI
23	Nierhaus A, Linssen J, Wichmann D, Braune S and Kluge S: Use of a weighted, automated analysis of the differential blood count to differentiate sepsis from non-infectious systemic inflammation: The intensive care infection score (ICIS). Inflamm Allergy Drug Targets. 11:109–115. 2012. View Article : Google Scholar : PubMed/NCBI
24	Kondo Y, Abe T, Kohshi K, Tokuda Y, Cook EF and Kukita I: Revised trauma scoring system to predict in-hospital mortality in the emergency department: Glasgow coma scale, age, and systolic blood pressure score. Crit Care. 15:R1912011. View Article : Google Scholar : PubMed/NCBI
25	Hewett PW: Vascular endothelial cells from human micro- and macrovessels: Isolation, characterisation and culture. Methods Mol Biol. 467:95–111. 2009. View Article : Google Scholar : PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Collins PE, O'Carroll C and Carmody RJ: Measurement of NF-κB transcriptional activity and identification of NF-κB cis-regulatory elements using luciferase assays. Methods Mol Biol. 1280:25–43. 2015. View Article : Google Scholar : PubMed/NCBI
28	Riedel S and Carroll KC: Early identification and treatment of pathogens in sepsis: Molecular diagnostics and antibiotic choice. Clin Chest Med. 37:191–207. 2016. View Article : Google Scholar : PubMed/NCBI
29	Brown KA, Brown GA, Lewis SM, Beale R and Treacher DF: Targeting cytokines as a treatment for patients with sepsis: A lost cause or a strategy still worthy of pursuit? Int Immunopharmacol. 36:291–299. 2016. View Article : Google Scholar : PubMed/NCBI
30	Yang CH, Kao MC, Shih PC, Li KY, Tsai PS and Huang CJ: Simvastatin attenuates sepsis-induced blood-brain barrier integrity loss. J Surg Res. 194:591–598. 2015. View Article : Google Scholar : PubMed/NCBI
31	Lin WC, Chen CW, Huang YW, Chao L, Chao J, Lin YS and Lin CF: Kallistatin protects against sepsis-related acute lung injury via inhibiting inflammation and apoptosis. Sci Rep. 5:124632015. View Article : Google Scholar : PubMed/NCBI
32	Bird L: Inflammation: Hope for sepsis treatment. Nat Rev Drug Discov. 9:516–517. 2010. View Article : Google Scholar : PubMed/NCBI
33	Cai B, Deitch EA and Ulloa L: Novel insights for systemic inflammation in sepsis and hemorrhage. Mediators Inflamm. 2010:6424622010. View Article : Google Scholar : PubMed/NCBI
34	Shao H, Wang C, Zhu W, Huang X, Guo Z, Zhang H and Qin B: Influence of simvastatin treatment on Toll-like receptor 4 in monocytes of peripheral blood in patients with sepsis and severe sepsis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 28:159–163. 2016.(In Chinese). PubMed/NCBI
35	Zhou S, Sun Y, Zhuang Y, Zhao W and Chen Y, Jiang B, Guo C, Zhang Z, Peng H and Chen Y: Effects of kallistatin on oxidative stress and inflammation on renal ischemia-reperfusion injury in mice. Curr Vasc Pharmacol. 13:265–273. 2015. View Article : Google Scholar : PubMed/NCBI
36	Lee SK, Kim YC, Song SB and Kim YS: Stabilization and translocation of p53 to mitochondria is linked to Bax translocation to mitochondria in simvastatin-induced apoptosis. Biochem Biophys Res Commun. 391:1592–1597. 2010. View Article : Google Scholar : PubMed/NCBI
37	Patassini S, Giampà C, Martorana A, Bernardi G and Fusco FR: Effects of simvastatin on neuroprotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington's disease. Neurosci Lett. 448:166–169. 2008. View Article : Google Scholar : PubMed/NCBI
38	Chao J, Yin H, Yao YY, Shen B, Smith RS Jr and Chao L: Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther. 17:1201–1213. 2006. View Article : Google Scholar : PubMed/NCBI